Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2251 to 2265 of 7681 results

  1. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection

  3. Troriluzole for spinocerebellar ataxia ID 6456

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing (MTG12)

    Evidence-based recommendations on EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing.

    Medical technologies guidance
    Last updated
    8 October 2019
    View recommendations

    Sections for MTG12

  5. Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034

      Status ...

    Technology appraisal guidance
    Topic selection

  6. The Debrisoft monofilament debridement pad for use in acute or chronic wounds (MTG17)

    Evidence-based recommendations on the Debrisoft monofilament debridement pad for use in acute or chronic wounds.

    Medical technologies guidance
    Last updated
    25 March 2019
    View recommendations

    Sections for MTG17

  7. Type 2 diabetes in adults: management (medicines update)

    In development [GID-NG10336] Expected publication date: 19 June 2025

    NICE guideline
    In development

  8. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Targeted Muscle Reinnervation for refractory pain after limb amputation

    In development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    In development

  10. Transcatheter aortic valve implantation for native aortic valve regurgitation

    In development [GID-IPG10357] Expected publication date: 11 June 2025

    Interventional procedures guidance
    In development

  11. Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions

    Awaiting development [GID-IPG10409] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  12. Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments [ID6388]

    Awaiting development [GID-TA11468] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [ID6455]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

    Awaiting development [GID-TA10757] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development